Blocking of VEGFR-ligand interaction has been a validated approach in drug development for CNV, as seen with the clinical success of bevacizumab (Avastin) and ranibizumab (Lucentis) in AMD. The gene discussed is KDR; the disease is age-related macular degeneration.